Arrowhead Pharmaceuticals, Inc. (ARWR)

How it makes money

In fiscal 2025 Arrowhead earned essentially nothing from selling medicines: REDEMPLO was approved only in November 2025, after the year closed. All of the $829.4 million of revenue came from license and collaboration agreements — upfront payments, development milestones and the sale of rights, recognised under accounting rules that spread or trigger the income as contractual obligations are met. The 10-K attributes $696.8 million to the Sarepta collaboration signed in November 2024, $130.0 million to the sale of Greater China rights to plozasiran by subsidiary Visirna to Sanofi, and $2.6 million to GSK. The company describes this partnering strategy as a source of non-dilutive capital to fund its wholly-owned programs. This makes revenue extremely lumpy: the same line was $3.6 million in fiscal 2024 and $240.7 million in fiscal 2023. Arrowhead also raises cash outside the income statement, through a $500.0 million senior secured facility with Sixth Street and royalty financing arrangements.

Arrowhead's defence is its intellectual property and platform know-how. The 10-K states the company controls roughly 643 issued patents — 404 of them on RNAi trigger molecules and 159 on targeting groups — plus about 833 pending applications across 103 patent families, together with technology acquired from Novartis and a licence to Alnylam intellectual property covering 30 undisclosed gene targets. That the world's largest drug companies repeatedly pay upfront to license TRiM programs is evidence outsiders value the platform. The advantage is narrow rather than wide: the company itself warns that its ability to protect its patents is uncertain, that licence agreements can be terminated, and that it has been subject to patent infringement claims — in September 2025 it filed a declaratory judgment action against Ionis Pharmaceuticals. With a single approved product and no established commercial franchise, the moat rests on patents and scientific lead, not on customers who would find it hard to leave.

The underlying demand is defensive: patients with Familial Chylomicronemia Syndrome, severe hypertriglyceridemia or rare neuromuscular disease need treatment regardless of the economic cycle, and prescriptions are paid by insurers and public health systems rather than out of discretionary household spending. What is volatile is not demand but Arrowhead's reported revenue, because in fiscal 2025 that revenue was contractual rather than commercial: $829.4 million in 2025 against $3.6 million in 2024 and $240.7 million in 2023, swinging with the timing of partnership signings and milestone triggers. Beginners should read the swing as contract timing, not as a cyclical business. The real drivers here are regulatory: approval decisions, the size of the labelled patient population, and the reimbursement levels insurers agree to — the company notes it is building a larger commercial organisation for severe hypertriglyceridemia, a much higher-prevalence indication than the rare disease it launched in.

Key risks

• Everything depends on candidates that are not yet approved — The company states that its prospects substantially depend on the success of its clinical-stage product candidates, and that if it and its licensees cannot obtain approval and commercialise them — or cannot successfully commercialise REDEMPLO — the business could be materially harmed. Clinical development is described as lengthy, expensive and uncertain, earlier results may not predict later ones, and trials may reveal significant adverse events or toxicities that block approval or market acceptance.
• Milestone income is controlled by the partners, not by Arrowhead — The 10-K states that the company's ability to generate milestone and royalty payments under its licensing and collaboration agreements is substantially controlled by its partners, and that it will likely need other sources of financing to keep developing its own candidates. It adds that it may lose considerable control over its intellectual property and may not receive the anticipated revenue in strategic transactions, particularly where the consideration depends on development or sales milestones being achieved.
• A history of losses and the need for substantial further funding — Among its financial risk factors the company lists a history of net losses that it expects to continue, with no assurance it will achieve or maintain profitability, and states that it will require substantial additional funds to complete its research and development activities. It also warns that operating results may fluctuate significantly, making them hard to predict and liable to fall below expectations or guidance.
• Covenants on the Sixth Street secured debt — The company discloses that the terms of its Sixth Street financing agreement and its indebtedness could adversely affect operations and limit its ability to plan for or respond to changes in the business, and that failure to comply with the restrictions could accelerate repayment of existing debt. The facility, entered into in August 2024, is a senior secured term loan of up to $500.0 million over seven years, with $400.0 million funded at closing, and it carries a liquidity covenant.
• Reimbursement, pricing and generic competition — The company states that successful commercialisation of REDEMPLO will depend in part on government authorities and health insurers setting adequate reimbursement levels and pricing policies, and notes significant uncertainty over the reimbursement status of newly approved drugs. It separately warns that approval of generic versions, or a failure to obtain appropriate data or market exclusivity periods, could adversely affect REDEMPLO sales.
• Dependence on third parties for manufacturing and trials — The company discloses that it has limited manufacturing capability and capacity and must rely on third-party manufacturers for clinical supplies and commercial product; if they fail to meet their obligations, development and commercialisation could be adversely affected. It relies on third parties to run its clinical trials as well, and notes it may have difficulty expanding operations as it moves toward commercialising drugs.
• Patent protection is uncertain and contested — Under intellectual property risks the company states that its ability to protect its patents and other proprietary rights is uncertain, exposing it to possible loss of competitive advantage; that it is party to technology licence agreements which, if terminated, could seriously harm its technology and business; and that it may be, and has been, subject to patent infringement claims that could bring substantial costs and liability and prevent it from commercialising potential products.

Top customers account for 84% of revenue

Concentration is extreme, because in fiscal 2025 Arrowhead's customers were three pharmaceutical partners, not patients. The 10-K reports $696.8 million of revenue recorded on the Sarepta collaboration, $130.0 million on the Sanofi transaction through subsidiary Visirna and $2.6 million on GSK, against total revenue of $829.4 million — so Sarepta alone accounted for roughly 84% and the three together for essentially the whole of it. The filing does not present this as a named customer-concentration disclosure; the share is read directly from the revenue figures the company states in its Management's Discussion and Analysis. This concentration should ease if REDEMPLO, approved in November 2025, builds genuine product sales.